MAPT and Alzheimer disease: Current understanding of AD pathophysiology and neurodegeneration suggests that the NFT accumulation is closely correlated with clinical disease progression and precedes clinical symptoms, making tau a promising biomarker for disease diagnosis and clinical trial design5,6.